Conference Reports for NATAP

64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013 Back

Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Moderate or Severe Hepatic Impairment       Reported by Jules Levin AASLD 2013 Nov 1-4 Wash DC   Polina German,1 Anita Mathias,1 Jenny C. Yang,1 Lindsay McNair,1 Gong Shen,1 Mona Vimal,1 Edward J. Gane,2 William B. Smith,3 Gernot K. Klein,4 Thomas C. Marbury,5 Eric Lawitz6 1Gilead Sciences, Inc., Foster City, CA; 2New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 3New Orleans Center for Clinical Research, Knoxville, TN; 4APEX Research, Munich, Germany; 5Orlando Clinical Research Center, Orlando, FL; 6Texas Liver Institute, San Antonio, TX